Adenoid cystic carcinoma of the trachea and bronchus - A clinicopathologic study with DNA flow cytometric analysis and oncogene expression

Chih Ming Lin, Anna Fen Yau Li, Li Hwa Wu, Yu Chung Wu, Frank Cheau Feng Lin, Liang Shun Wang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: Adenoid cystic carcinoma (ACC) of the tracheobronchial tree is quite uncommon. The clinicopathologic analysis and the therapeutic outcomes of tracheobronchial ACC have been reported earlier. However, their biological behavior should differ from other tracheal neoplasms. Thus, DNA flow cytometric analysis and biomarkers of p53, HER-2/neu and COX-2 for tracheobronchial ACC were investigated in order to evaluate their clinicopathological significance. Methods: Between 1985 and 1999, nine patients with tracheobronchial ACC were included for the study. All the patients had pathologically confirmed ACC. Five were male and four were female. Eight patients underwent surgical resections. Seven paraffin embedded tumors from six patients were available for DNA flow cytomeric analysis and immunohistochemical staining of p53, HER-2/neu and COX-2. Results: Histologically, nine pathologic specimens from eight surgical patients (including one patient received operation twice) showed one grade I, five grade II and three grade III. The mitotic activity, lymphatic invasion and vascular invasion were more frequent in advanced grading tumor. The higher grade tumors seemed to be associated with a higher synthetic phase fraction (SPF). Immunohistochemically, except for one grade II tumor showing positive expression of HER-2/neu, all the seven tumorous samples revealed negative expressions of p53, COX-2 and HER-2/neu. The patient with positive HER-2/neu tumor had distant metastases 4 years after surgery. Conclusions: Complete surgical resection may provide best survival for tracheobronchial ACC. The DNA ploidy and SPF may correlate with tumor grading or metastasis. The overexpressions of HER-2/neu, p53 and COX-2 may impact the prognosis in patients with stage I non-small cell lung cancer, but did not express difference in our patients.

Original languageEnglish
Pages (from-to)621-625
Number of pages5
JournalEuropean Journal of Cardio-thoracic Surgery
Volume22
Issue number4
DOIs
Publication statusPublished - Oct 2002
Externally publishedYes

Fingerprint

Adenoid Cystic Carcinoma
Bronchi
Trachea
Oncogenes
DNA
Neoplasm Grading
Tracheal Neoplasms
Neoplasms
Neoplasm Metastasis
Ploidies
Non-Small Cell Lung Carcinoma
Paraffin
Blood Vessels
Biomarkers
Staining and Labeling
Survival

Keywords

  • Adenoid cystic carcinoma
  • Biomarkers
  • DNA ploidy
  • Trachea

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Adenoid cystic carcinoma of the trachea and bronchus - A clinicopathologic study with DNA flow cytometric analysis and oncogene expression. / Lin, Chih Ming; Li, Anna Fen Yau; Wu, Li Hwa; Wu, Yu Chung; Lin, Frank Cheau Feng; Wang, Liang Shun.

In: European Journal of Cardio-thoracic Surgery, Vol. 22, No. 4, 10.2002, p. 621-625.

Research output: Contribution to journalArticle

Lin, Chih Ming ; Li, Anna Fen Yau ; Wu, Li Hwa ; Wu, Yu Chung ; Lin, Frank Cheau Feng ; Wang, Liang Shun. / Adenoid cystic carcinoma of the trachea and bronchus - A clinicopathologic study with DNA flow cytometric analysis and oncogene expression. In: European Journal of Cardio-thoracic Surgery. 2002 ; Vol. 22, No. 4. pp. 621-625.
@article{1011e41b9b5f4ab09a49b2df74a20d6e,
title = "Adenoid cystic carcinoma of the trachea and bronchus - A clinicopathologic study with DNA flow cytometric analysis and oncogene expression",
abstract = "Objective: Adenoid cystic carcinoma (ACC) of the tracheobronchial tree is quite uncommon. The clinicopathologic analysis and the therapeutic outcomes of tracheobronchial ACC have been reported earlier. However, their biological behavior should differ from other tracheal neoplasms. Thus, DNA flow cytometric analysis and biomarkers of p53, HER-2/neu and COX-2 for tracheobronchial ACC were investigated in order to evaluate their clinicopathological significance. Methods: Between 1985 and 1999, nine patients with tracheobronchial ACC were included for the study. All the patients had pathologically confirmed ACC. Five were male and four were female. Eight patients underwent surgical resections. Seven paraffin embedded tumors from six patients were available for DNA flow cytomeric analysis and immunohistochemical staining of p53, HER-2/neu and COX-2. Results: Histologically, nine pathologic specimens from eight surgical patients (including one patient received operation twice) showed one grade I, five grade II and three grade III. The mitotic activity, lymphatic invasion and vascular invasion were more frequent in advanced grading tumor. The higher grade tumors seemed to be associated with a higher synthetic phase fraction (SPF). Immunohistochemically, except for one grade II tumor showing positive expression of HER-2/neu, all the seven tumorous samples revealed negative expressions of p53, COX-2 and HER-2/neu. The patient with positive HER-2/neu tumor had distant metastases 4 years after surgery. Conclusions: Complete surgical resection may provide best survival for tracheobronchial ACC. The DNA ploidy and SPF may correlate with tumor grading or metastasis. The overexpressions of HER-2/neu, p53 and COX-2 may impact the prognosis in patients with stage I non-small cell lung cancer, but did not express difference in our patients.",
keywords = "Adenoid cystic carcinoma, Biomarkers, DNA ploidy, Trachea",
author = "Lin, {Chih Ming} and Li, {Anna Fen Yau} and Wu, {Li Hwa} and Wu, {Yu Chung} and Lin, {Frank Cheau Feng} and Wang, {Liang Shun}",
year = "2002",
month = "10",
doi = "10.1016/S1010-7940(02)00406-2",
language = "English",
volume = "22",
pages = "621--625",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Adenoid cystic carcinoma of the trachea and bronchus - A clinicopathologic study with DNA flow cytometric analysis and oncogene expression

AU - Lin, Chih Ming

AU - Li, Anna Fen Yau

AU - Wu, Li Hwa

AU - Wu, Yu Chung

AU - Lin, Frank Cheau Feng

AU - Wang, Liang Shun

PY - 2002/10

Y1 - 2002/10

N2 - Objective: Adenoid cystic carcinoma (ACC) of the tracheobronchial tree is quite uncommon. The clinicopathologic analysis and the therapeutic outcomes of tracheobronchial ACC have been reported earlier. However, their biological behavior should differ from other tracheal neoplasms. Thus, DNA flow cytometric analysis and biomarkers of p53, HER-2/neu and COX-2 for tracheobronchial ACC were investigated in order to evaluate their clinicopathological significance. Methods: Between 1985 and 1999, nine patients with tracheobronchial ACC were included for the study. All the patients had pathologically confirmed ACC. Five were male and four were female. Eight patients underwent surgical resections. Seven paraffin embedded tumors from six patients were available for DNA flow cytomeric analysis and immunohistochemical staining of p53, HER-2/neu and COX-2. Results: Histologically, nine pathologic specimens from eight surgical patients (including one patient received operation twice) showed one grade I, five grade II and three grade III. The mitotic activity, lymphatic invasion and vascular invasion were more frequent in advanced grading tumor. The higher grade tumors seemed to be associated with a higher synthetic phase fraction (SPF). Immunohistochemically, except for one grade II tumor showing positive expression of HER-2/neu, all the seven tumorous samples revealed negative expressions of p53, COX-2 and HER-2/neu. The patient with positive HER-2/neu tumor had distant metastases 4 years after surgery. Conclusions: Complete surgical resection may provide best survival for tracheobronchial ACC. The DNA ploidy and SPF may correlate with tumor grading or metastasis. The overexpressions of HER-2/neu, p53 and COX-2 may impact the prognosis in patients with stage I non-small cell lung cancer, but did not express difference in our patients.

AB - Objective: Adenoid cystic carcinoma (ACC) of the tracheobronchial tree is quite uncommon. The clinicopathologic analysis and the therapeutic outcomes of tracheobronchial ACC have been reported earlier. However, their biological behavior should differ from other tracheal neoplasms. Thus, DNA flow cytometric analysis and biomarkers of p53, HER-2/neu and COX-2 for tracheobronchial ACC were investigated in order to evaluate their clinicopathological significance. Methods: Between 1985 and 1999, nine patients with tracheobronchial ACC were included for the study. All the patients had pathologically confirmed ACC. Five were male and four were female. Eight patients underwent surgical resections. Seven paraffin embedded tumors from six patients were available for DNA flow cytomeric analysis and immunohistochemical staining of p53, HER-2/neu and COX-2. Results: Histologically, nine pathologic specimens from eight surgical patients (including one patient received operation twice) showed one grade I, five grade II and three grade III. The mitotic activity, lymphatic invasion and vascular invasion were more frequent in advanced grading tumor. The higher grade tumors seemed to be associated with a higher synthetic phase fraction (SPF). Immunohistochemically, except for one grade II tumor showing positive expression of HER-2/neu, all the seven tumorous samples revealed negative expressions of p53, COX-2 and HER-2/neu. The patient with positive HER-2/neu tumor had distant metastases 4 years after surgery. Conclusions: Complete surgical resection may provide best survival for tracheobronchial ACC. The DNA ploidy and SPF may correlate with tumor grading or metastasis. The overexpressions of HER-2/neu, p53 and COX-2 may impact the prognosis in patients with stage I non-small cell lung cancer, but did not express difference in our patients.

KW - Adenoid cystic carcinoma

KW - Biomarkers

KW - DNA ploidy

KW - Trachea

UR - http://www.scopus.com/inward/record.url?scp=0036804601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036804601&partnerID=8YFLogxK

U2 - 10.1016/S1010-7940(02)00406-2

DO - 10.1016/S1010-7940(02)00406-2

M3 - Article

VL - 22

SP - 621

EP - 625

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 4

ER -